<!DOCTYPE HTML>
<!--
	ZeroFour by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
<head>
<title>Tumor pH imaging | Longo Lab</title>
<meta name="MobileOptimized" content="width">
<meta name="HandheldFriendly" content="true">
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />

<meta name="description"
	content="We are interested in developing novel MRI contrast agents: high-relaxivity Gd-based, blood-pool contrast agents, diamagnetic CEST (iopamidol, excipients)." />
<meta name="keywords"
	content="molecular imaging, tumor, gadolinium, contrast agent, X-ray, radiographic, kidney, acidosis, metabolism, acute kidney injury, angiogenesis, MRI, magnetic resonance imaging, CEST, vascularization" />
<meta name="robots" content="noindex, nofollow">
<meta name="revisit-after" content="3 month">

<!-- imaging, x-ray, tumor -->
<!--[if lte IE 8]><script src="assets/js/ie/html5shiv.js"></script><![endif]-->
<link rel="stylesheet" href="assets/css/main.css" />
<!--[if lte IE 8]><link rel="stylesheet" href="assets/css/ie8.css" /><![endif]-->
<!--[if lte IE 9]><link rel="stylesheet" href="assets/css/ie9.css" /><![endif]-->
</head>
<body class="homepage">
	<div id="page-wrapper">

		<!-- Header -->
		<div id="header-wrapper">
			
			<!-- logo unito -->
			<div class="unito-logo-container">
			 <img src="images/logo_unito.jpg" class="unito-logo">
			 <div>
			 <a href="http://www.unito.it" title="University of Torino" target="_blank" id="unito-logo" class="unito-logo-text"  style="text-decoration: none";><p>University of Torino</a>
	          <a href="http://www.cim.unito.it" title="Molecular Imaging Center" target="_blank" style="text-decoration: none" class="unito-logo-text";>Molecular Imaging Center</p></a>          
	          </div>
			</div>
			
			
			<div class="container">
					
				<!-- Header -->
				<header id="header" style="margin: -30px 0 30px 0;">
					<div class="inner">
					
						<!-- Logo -->
						<h1>
							<a href="home.html" id="logo">DARIO LONGO LAB</a>
							<div>
								<p style="color: gray; font-size=12px;" >Imaging Tumor Microenvironment</p>

							</div>
						</h1>
						<!-- Nav -->
						<nav id="nav">
							<ul>
								<li><a href="home.html">Home</a></li>
								<li class="current_page_item"><a
									href="research_overview.html">Research</a>
									<ul>
										<li><a href="research_overview.html">Overview</a></li>
										<li><a href="research_probes.html">MRI probes</a></li>
										<li><a href="research_angiogenesis.html">Tumor
												angiogenesis</a>
										<li>
										<li><a href="research_tumor_pH.html" font
											style="text-transform: none;">TUMOR pH IMAGING</a>
										<li>
										<li><a href="research_kidney.html" font
											style="text-transform: none;">RENAL pH IMAGING</a></li>
									</ul></li>
								<li><a href="group.html">Group</a></li>
								<li><a href="publications.html">Publications</a></li>
								<li><a href="contact.html">Contact us</a></li>
							</ul>
						</nav>

					</div>
				</header>

			</div>
		</div>


		<!-- Main Wrapper -->
		<div id="main-wrapper">

			<div class="wrapper style3">
				<div class="inner">
					<section class="container box feature3">
						<div class="row">

							<article>

								<h3 font style="text-transform: none;">Investigating tumor pH imaging as a novel cancer biomarker</h3>
								<p align="justify">Tumor cells that live in conditions of hypoxia show an up-regulated glucose metabolism, because of hypoxia-induced shift toward 
								glycolysis. Tumor cells have evolved several sophisticated mechanisms to regulate pH homeostasis: they eliminate acidic catabolites
								by ion transporters and pumps to preserve a slightly alkaline intracellular pH (pHi), which is optimal for cell proliferation and 
								tumor survival.This behavior leads to enhanced acidification of the extracellular pH (pHe) to values in the range 6.5-7.0, which is
								a distinguishing feature of the tumor microenvironment. Imaging based methods have already been established, at a clinical level, 
								to assess glucose metabolism (by positron emission tomography - PET imaging of 18F-fluorodeoyglucose FDG tumor uptake), providing a
								formidable tool for evaluating treatment response. <br>Conversely, despite the excellent studies regarding tumor acidosis, we still 
								do not have an effective acid-base imaging protocol that allows the quantification of extracellular tumor pH and the assessment 
								of pHe related changes following therapeutic treatment. <br><strong>The focus of our research is to assess if pHe MRI imaging may be a 
								potential innovative non-invasive diagnostic tool, comparable and eventually alternative to nuclear medicine techniques (FDG-PET), 
								to evaluate treatment response to drugs targeting tumor metabolism.</strong> </p>


							</article>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<h3 font style="text-transform: none;">
												<font color="red">New Gd-based blood-pool agent</font></a>
											</h3>
											</br>
											<p>Gd-AAZTA-MADEC, an improved blood pool agent for
												DCE-MRI studies on mice</p>
										</header>
										<img src="images/Figure1C.png" alt="" style="width: 340px;">

										<p align="justify">
											In the past years several blood pool Gd-complexes, optimized
											for the clinical scenario, have been used in pre-clinical
											settings to report on vessel architecture and on tumor vessel
											permeability. Such Gd-based complexes have, unfortunately,
											sub-optimal contrast properties when used with the recently
											developed low-field (1 Tesla) pre-clinical MRI scanners in
											addition to sub-optimal binding properties to mouse serum
											albumin. We have developed a new blood pool Gd(III)-based CA
											<a class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank"><font color="blue">[Longo et al.
													2016]</font></a>, comparing its remarkable MRI contrast properties in
											comparison to the clinically approved MS-325 (Vasovist or
											Ablavar) and to B22956/1.
										</p>
										<img src="images/Figure5.tif" alt="" style="width: 340px;">
										<p align="justify">Gd-AAZTA-MADEC showed stronger binding
											affinity to HSA, higher relaxivity both with human and with
											mouse serum albumin (at 40 MHz and 37°C), as well as more
											prolonged blood circulation time with respect to the other
											CAs. These properties turned out into brightest and prolonged
											MIP angiographic images.</p>
										<footer>
											<a href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank" class="button alt icon fa-file-o">Continue
												Reading</a>
										</footer>
									</article>
								</section>
							</div>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<h3 font style="text-transform: none;">
												<font color="red">Transforming CT to MRI-CEST
													contrast agents</font></a>
											</h3>
											<p>Nonionic Iodinated Radiographic Molecules as MRI-CEST
												Tumor Perfusion Agents</p>
										</header>
										<img src="images/Figure1C.png" alt="" style="width: 340px;">

										<p align="justify">
											We have developed a new blood pool Gd(III)-based CA <a
												class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank"><font color="blue">[Longo et al.
													2016]</font></a>, comparing its remarkable MRI contrast properties in
											comparison to the clinically approved MS-325 (Vasovist or
											Ablavar) and to B22956/1.
										</p>
										<img src="images/Figure5.tif" alt="" style="width: 340px;">
										<p align="justify">Gd-AAZTA-MADEC showed stronger binding
											affinity to HSA, higher relaxivity both with human and with
											mouse serum albumin (at 40 MHz and 37°C), as well as more
											prolonged blood circulation time with respect to the other
											CAs. These properties turned out into brightest and prolonged
											MIP angiographic images.</p>
										<footer>
											<a href="https://www.ncbi.nlm.nih.gov/pubmed/26460826"
												target="_blank" class="button alt icon fa-file-o">Continue
												Reading</a>
										</footer>
									</article>
								</section>
							</div>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<h3 font style="text-transform: none;">
												<font color="red">New MRI-CEST contrast agents</font></a>
											</h3>
											</br>
											<p>Assessment of tumour perfusion using X-ray iodinated
												agents</p>
										</header>
										<img src="images/Figure1C.png" alt="" style="width: 340px;">

										<p align="justify">
											Gd-based agents are an indispensable part of MRI examinations
											to characterize tumor physiology and delineate tumor margins.
											However, in the past decades, two major clinical studies
											questioned their safety profiles [1] and alternatives to
											Gd-based agents are not readily available. Iodinated contrast
											media (CM) are commonly used x-ray contrast agents, playing a
											key-role in oncological imaging [2]. Recently we have shown <a
												class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/26460826"
												target="_blank"><font color="blue"> [Longo et al.
													2016] </font></a> that iodinated CM can provide contrast enhancement
											in tumors (by exploiting the MRI-CEST approach) that is
											correlated with corresponding CT enhanced images [3]. In
											addition, both iodinated and Gd-based CM have similar
											molecular weights, likely possessing similar tumor perfusion
											properties. We compared several iodinated CM with a Gd-based
											contrast agent to provide MR enhanced-tumor images and
											perfusion values <a class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/27572810"
												target="_blank"><font color="blue"> [Anemone et
													al. 2017] </font></a>.
										</p>
										<img src="images/Figure5.tif" alt="" style="width: 340px;">
										<p align="justify">This work is the first comparison of
											tumor contrast enhancements and tumor perfusion values using
											iodinated CM and a Gd-based agent in a preclinical breast
											tumor model. The obtained enhancement and perfusion maps by
											both MRI-based approaches proved that the spatial information
											was similar, suggesting that iodinated CM, within the
											MRI-CEST approach, might be able to replace Gd-based agents.</p>
										<footer>
											<a href="https://www.ncbi.nlm.nih.gov/pubmed/27572810"
												target="_blank" class="button alt icon fa-file-o">Continue
												Reading</a>
										</footer>
									</article>
								</section>
							</div>

							<div class="4u 12u(mobile)">

								<!-- Spotlight -->
								<section>

									<article>

										<header>
											<h3 font style="text-transform: none;">
												<font color="red">Gd-based probes for Molecular
													Imaging</font></a>
											</h3>
											</br>
											<p>Assessment of tumour perfusion using X-ray iodinated
												agents</p>
										</header>
										<img src="images/Figure1C.png" alt="" style="width: 340px;">

										<p align="justify">
											In the past years several blood pool Gd-complexes, optimized
											for the clinical scenario, have been used in pre-clinical
											settings to report on vessel architecture and on tumor vessel
											permeability. Such Gd-based complexes have, unfortunately,
											sub-optimal contrast properties when used with the recently
											developed low-field (1 Tesla) pre-clinical MRI scanners in
											addition to sub-optimal binding properties to mouse serum
											albumin. We have developed a new blood pool Gd(III)-based CA
											<a class="html"
												href="https://www.ncbi.nlm.nih.gov/pubmed/26480471"
												target="_blank"><font color="blue">[Longo et al.
													2016]</font></a>, comparing its remarkable MRI contrast properties in
											comparison to the clinically approved MS-325 (Vasovist or
											Ablavar) and to B22956/1.
										</p>
										<img src="images/Figure5.tif" alt="" style="width: 340px;">
										<p align="justify">Gd-AAZTA-MADEC showed stronger binding
											affinity to HSA, higher relaxivity both with human and with
											mouse serum albumin (at 40 MHz and 37°C), as well as more
											prolonged blood circulation time with respect to the other
											CAs. These properties turned out into brightest and prolonged
											MIP angiographic images.</p>
										<footer>
											<a href="https://www.ncbi.nlm.nih.gov/pubmed/27572810"
												target="_blank" class="button alt icon fa-file-o">Continue
												Reading</a>
										</footer>
									</article>
								</section>
							</div>


						</div>

					</section>

				</div>
			</div>
		</div>


	</div>

	<!-- Scripts -->

	<script src="assets/js/jquery.min.js"></script>
	<script src="assets/js/jquery.dropotron.min.js"></script>
	<script src="assets/js/skel.min.js"></script>
	<script src="assets/js/skel-viewport.min.js"></script>
	<script src="assets/js/util.js"></script>
	<!--[if lte IE 8]><script src="assets/js/ie/respond.min.js"></script><![endif]-->
	<script src="assets/js/main.js"></script>

</body>
</html>